Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for injectable HRS5580, which will conduct clinical trials in the near future.

HRS5580 for injection is a selective neurokinpeptide-1 (NK-1) receptor antagonist. It blocks P substance binding to NK-1 receptors through high affinity and exerts a strong antiemetic effect. This variety has differentiated advantages such as high solubility, good safety, and long-term effect. According to inquiries, the same target drugs that have been marketed globally, such as Heron's aripitane injection emulsion (APONVIE®), are all short-acting NK-1 antagonists, and no long-term formulation has yet been approved. Up to now, the total R&D investment for HRS5580 related projects is about 57.7 million yuan (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.